Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Предменструальный синдром
Предменструальный синдром
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Обзор. Известно более 150 симптомов предменструального синдрома, которые в различных сочетаниях появляются в лютеиновую фазу цикла и исчезают с наступлением менструации у 90% женщин. Рассмотрены вопросы этиологии, патогенеза, клинических диагностических признаков, критериев и шкал их оценки, а также лечения предменструального синдрома.
Ключевые слова: предменструальный синдром.
Key words: premenstrual syndrome.
Ключевые слова: предменструальный синдром.
________________________________________________
Key words: premenstrual syndrome.
Полный текст
Список литературы
1. Кузнецова М.Н. Предменструальный синдром и его лечение. Акуш. и гинекол. 1973; 5: 55–9.
2. Прилепская В.Н., Межевитинова Е.А. Предменструальный синдром. Гинекол. эндокринол. 2007; 7 (4): 210–4.
3. Татарчук Т.Ф., Венцковская И.Б., Шевчук Т.В. Предменструальный синдром. Эндокринная гинекология. Киев: Заповит, 2003.
4. Эндокринная гинекология. Под ред. Т.Ф.Татарчук, Я.П.Сольский. Киев: Заповит, 2003.
5. Accortt EE, Allen JJ. Frontal EEG asymmetry and premenstrual dysphoric symptomatology. J Abnorm Psychol 2006; 115 (1): 179–84.
6. Baehr E, Rosenfeld P, Miller L, Baehr R. Premenstrual dysphoric disorder and changes in frontal alpha asymmetry. Int J Psychophysiol 2004; 52 (2): 159–67.
7. Benitez A, Gunstad J, Hughes J. Troponin and S100 beta are associated with depression in healthy older adults. Aging Ment Health 2009; 13 (6): 894–8.
8. Bertone-Johnson ER, Chocano-Bedoya PO. Dietary vitamin D intake, 25-hydroxyvitamin D(3) levels and premenstrual syndrome in a college-aged population. J Steroid Biochem Mol Biol 2010.
9. Böttiger BW, Möbes S, Glätzer R. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 2001; 103 (22): 2694–8.
10. Brown J, O’Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD001396.
11. Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol 1994; 101: 689–95.
12. Cho SH, Kim J. Efficacy of acupuncture in management of premenstrual syndrome: a systematic review. Complement Ther Med 2010; 18 (2): 104–11.
13. Coffee AL, Kuehl TJ, Sulak PJ. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives. Pharmacotherapy 2008; 28 (5): 576–83.
14. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8 (2): 122–8.
15. Diagnostic and Statistical Manual of mental disorders, DSM-IV) для оценки состояния пациенток (Moira Connolly, Advances in Psychiatric Treatment 2001; 7: 469–77.
16. Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41–9.
17. Eriksson O, Wall A, Marteinsdottir I. Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Res 2006; 146 (2): 107–16.
18. Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD003415.
19. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996; 65: 97–106.
20. Gonda X, Telek T, Juhász G et al. Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (8): 1782–8.
21. Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr 2008; 13 (7): 566–72.
22. Huo L, Straub RE, Roca C. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007; 62 (8): 925–33.
23. Inoue Y, Terao T, Iwata N. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology (Berl) 2007; 190 (2): 213–9.
24. Jovanovic H, Cerin A, Karlsson P. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006; 148 (2–3): 185–93.
25. Kikuchi H, Nakatani Y, Seki Y. Decreased blood serotonin in the premenstrual phase enhances negative mood in healthy women. J Psychosom Obstet Gynaecol 2010; 31 (2): 83–9.
26. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78 (1): 16–25.
27. Korfias S, Stranjalis G, Papadimitriou A. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 2006; 13 (30): 3719–31.
28. Korzekwa MI, Lamont JA, Steiner M. Late luteal phase dysphoric disorder and the thyroid axis revisited. J Clin Endocrinol Metab 1996; 81 (6): 2280–4.
29. Kuzelova H, Ptacek R, Macek M. The serotonin transporter gene (5-HTT) variant and psychiatric disorders: review of current literature. Neuro Endocrinol Lett 2010; 31 (1): 4–10.
30. Lonsdorf TB, Rück C, Bergström J. The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (8): 1479–83.
31. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD006586.
32. Magnay JL, El-Shourbagy M, Fryer A.A. Analysis of the serotonin transporter promoter rs25531 polymorphism in premenstrual dysphoric disorder. Am J Obstet Gynecol 2010.
33. Magnay JL, Ismail KM, Chapman G. Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder. Am J Obstet Gynecol 2006; 195 (5): 1254–9.
34. Pearlstein T, Steiner M., Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 2008; 33 (4): 291–301.
35. Pedersen A, Diedrich M, Kaestner F. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (8): 1789–92.
36. Poiană C, Muşat M, Carsote M, Chiriţă C. Premenstrual dysphoric disorder: neuroendocrine interferences. Rev Med Chir Soc Med Nat Iasi 2009; 113 (4): 996–1000.
37. Radhika D. Rible, Daniel R. Mishell Jr, Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. Contraception 2009; 79 (3): 182–8.
38. Rao H, Gillihan SJ, Wang J. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry 2007; 62 (6): 600–6.
39. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003; 28 (Suppl. 3): 39–53.
40. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl. 9): 729–41.
41. Rendas-Baum R, Yang M, Gricar J, Wallenstein GV. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder. Appl Health Econ Health Policy 2010; 8 (2): 129–40.
42. Rosenfeld R, Livne D, Nevo O. Hormonal and volume dysregulation in women with premenstrual syndrome. Hypertension 2008; 51 (4): 1225–30.
43. Schmidt PJ, Grover GN, Roy-Byrne PP. Thyroid function in women with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76 (3): 671–4.
44. Silva CM, Gigante DP, Carret ML, Fassa AG. Population study of premenstrual syndrome. Rev Saude Publica 2006; 40 (1): 47–56.
45. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health 2003; 6: 203–9.
46. Steiner M, Streiner DL, Steinberg S et al. The measurement of premenstrual mood symptoms. J Affect Disord 1999; 53: 269–73.
47. Taneepanichskul S, Jaisamrarn U, Phupong V. Efficacy of Yasmin in premenstrual symptoms. Arch Gynecol Obstet 2007; 275 (6): 433–8.
48. Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health, 2010.
49. Halbreich U, Backstrom T, Eriksson E. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
50. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16 (3): e407–29.
51. Zhang Y, Rothermundt M, Peters M. S100B serum levels and word memory processing in remitted major depression as reflected by brain potentials. Neuropsychobiology 2009; 59 (3): 172–7.
2. Прилепская В.Н., Межевитинова Е.А. Предменструальный синдром. Гинекол. эндокринол. 2007; 7 (4): 210–4.
3. Татарчук Т.Ф., Венцковская И.Б., Шевчук Т.В. Предменструальный синдром. Эндокринная гинекология. Киев: Заповит, 2003.
4. Эндокринная гинекология. Под ред. Т.Ф.Татарчук, Я.П.Сольский. Киев: Заповит, 2003.
5. Accortt EE, Allen JJ. Frontal EEG asymmetry and premenstrual dysphoric symptomatology. J Abnorm Psychol 2006; 115 (1): 179–84.
6. Baehr E, Rosenfeld P, Miller L, Baehr R. Premenstrual dysphoric disorder and changes in frontal alpha asymmetry. Int J Psychophysiol 2004; 52 (2): 159–67.
7. Benitez A, Gunstad J, Hughes J. Troponin and S100 beta are associated with depression in healthy older adults. Aging Ment Health 2009; 13 (6): 894–8.
8. Bertone-Johnson ER, Chocano-Bedoya PO. Dietary vitamin D intake, 25-hydroxyvitamin D(3) levels and premenstrual syndrome in a college-aged population. J Steroid Biochem Mol Biol 2010.
9. Böttiger BW, Möbes S, Glätzer R. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 2001; 103 (22): 2694–8.
10. Brown J, O’Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD001396.
11. Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol 1994; 101: 689–95.
12. Cho SH, Kim J. Efficacy of acupuncture in management of premenstrual syndrome: a systematic review. Complement Ther Med 2010; 18 (2): 104–11.
13. Coffee AL, Kuehl TJ, Sulak PJ. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives. Pharmacotherapy 2008; 28 (5): 576–83.
14. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8 (2): 122–8.
15. Diagnostic and Statistical Manual of mental disorders, DSM-IV) для оценки состояния пациенток (Moira Connolly, Advances in Psychiatric Treatment 2001; 7: 469–77.
16. Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41–9.
17. Eriksson O, Wall A, Marteinsdottir I. Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Res 2006; 146 (2): 107–16.
18. Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD003415.
19. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996; 65: 97–106.
20. Gonda X, Telek T, Juhász G et al. Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (8): 1782–8.
21. Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr 2008; 13 (7): 566–72.
22. Huo L, Straub RE, Roca C. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007; 62 (8): 925–33.
23. Inoue Y, Terao T, Iwata N. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology (Berl) 2007; 190 (2): 213–9.
24. Jovanovic H, Cerin A, Karlsson P. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006; 148 (2–3): 185–93.
25. Kikuchi H, Nakatani Y, Seki Y. Decreased blood serotonin in the premenstrual phase enhances negative mood in healthy women. J Psychosom Obstet Gynaecol 2010; 31 (2): 83–9.
26. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78 (1): 16–25.
27. Korfias S, Stranjalis G, Papadimitriou A. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 2006; 13 (30): 3719–31.
28. Korzekwa MI, Lamont JA, Steiner M. Late luteal phase dysphoric disorder and the thyroid axis revisited. J Clin Endocrinol Metab 1996; 81 (6): 2280–4.
29. Kuzelova H, Ptacek R, Macek M. The serotonin transporter gene (5-HTT) variant and psychiatric disorders: review of current literature. Neuro Endocrinol Lett 2010; 31 (1): 4–10.
30. Lonsdorf TB, Rück C, Bergström J. The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (8): 1479–83.
31. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD006586.
32. Magnay JL, El-Shourbagy M, Fryer A.A. Analysis of the serotonin transporter promoter rs25531 polymorphism in premenstrual dysphoric disorder. Am J Obstet Gynecol 2010.
33. Magnay JL, Ismail KM, Chapman G. Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder. Am J Obstet Gynecol 2006; 195 (5): 1254–9.
34. Pearlstein T, Steiner M., Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 2008; 33 (4): 291–301.
35. Pedersen A, Diedrich M, Kaestner F. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (8): 1789–92.
36. Poiană C, Muşat M, Carsote M, Chiriţă C. Premenstrual dysphoric disorder: neuroendocrine interferences. Rev Med Chir Soc Med Nat Iasi 2009; 113 (4): 996–1000.
37. Radhika D. Rible, Daniel R. Mishell Jr, Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. Contraception 2009; 79 (3): 182–8.
38. Rao H, Gillihan SJ, Wang J. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry 2007; 62 (6): 600–6.
39. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003; 28 (Suppl. 3): 39–53.
40. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl. 9): 729–41.
41. Rendas-Baum R, Yang M, Gricar J, Wallenstein GV. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder. Appl Health Econ Health Policy 2010; 8 (2): 129–40.
42. Rosenfeld R, Livne D, Nevo O. Hormonal and volume dysregulation in women with premenstrual syndrome. Hypertension 2008; 51 (4): 1225–30.
43. Schmidt PJ, Grover GN, Roy-Byrne PP. Thyroid function in women with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76 (3): 671–4.
44. Silva CM, Gigante DP, Carret ML, Fassa AG. Population study of premenstrual syndrome. Rev Saude Publica 2006; 40 (1): 47–56.
45. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health 2003; 6: 203–9.
46. Steiner M, Streiner DL, Steinberg S et al. The measurement of premenstrual mood symptoms. J Affect Disord 1999; 53: 269–73.
47. Taneepanichskul S, Jaisamrarn U, Phupong V. Efficacy of Yasmin in premenstrual symptoms. Arch Gynecol Obstet 2007; 275 (6): 433–8.
48. Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health, 2010.
49. Halbreich U, Backstrom T, Eriksson E. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
50. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16 (3): e407–29.
51. Zhang Y, Rothermundt M, Peters M. S100B serum levels and word memory processing in remitted major depression as reflected by brain potentials. Neuropsychobiology 2009; 59 (3): 172–7.
2. Прилепская В.Н., Межевитинова Е.А. Предменструальный синдром. Гинекол. эндокринол. 2007; 7 (4): 210–4.
3. Татарчук Т.Ф., Венцковская И.Б., Шевчук Т.В. Предменструальный синдром. Эндокринная гинекология. Киев: Заповит, 2003.
4. Эндокринная гинекология. Под ред. Т.Ф.Татарчук, Я.П.Сольский. Киев: Заповит, 2003.
5. Accortt EE, Allen JJ. Frontal EEG asymmetry and premenstrual dysphoric symptomatology. J Abnorm Psychol 2006; 115 (1): 179–84.
6. Baehr E, Rosenfeld P, Miller L, Baehr R. Premenstrual dysphoric disorder and changes in frontal alpha asymmetry. Int J Psychophysiol 2004; 52 (2): 159–67.
7. Benitez A, Gunstad J, Hughes J. Troponin and S100 beta are associated with depression in healthy older adults. Aging Ment Health 2009; 13 (6): 894–8.
8. Bertone-Johnson ER, Chocano-Bedoya PO. Dietary vitamin D intake, 25-hydroxyvitamin D(3) levels and premenstrual syndrome in a college-aged population. J Steroid Biochem Mol Biol 2010.
9. Böttiger BW, Möbes S, Glätzer R. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 2001; 103 (22): 2694–8.
10. Brown J, O’Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD001396.
11. Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol 1994; 101: 689–95.
12. Cho SH, Kim J. Efficacy of acupuncture in management of premenstrual syndrome: a systematic review. Complement Ther Med 2010; 18 (2): 104–11.
13. Coffee AL, Kuehl TJ, Sulak PJ. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives. Pharmacotherapy 2008; 28 (5): 576–83.
14. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8 (2): 122–8.
15. Diagnostic and Statistical Manual of mental disorders, DSM-IV) для оценки состояния пациенток (Moira Connolly, Advances in Psychiatric Treatment 2001; 7: 469–77.
16. Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41–9.
17. Eriksson O, Wall A, Marteinsdottir I. Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Res 2006; 146 (2): 107–16.
18. Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD003415.
19. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996; 65: 97–106.
20. Gonda X, Telek T, Juhász G et al. Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (8): 1782–8.
21. Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr 2008; 13 (7): 566–72.
22. Huo L, Straub RE, Roca C. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007; 62 (8): 925–33.
23. Inoue Y, Terao T, Iwata N. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology (Berl) 2007; 190 (2): 213–9.
24. Jovanovic H, Cerin A, Karlsson P. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006; 148 (2–3): 185–93.
25. Kikuchi H, Nakatani Y, Seki Y. Decreased blood serotonin in the premenstrual phase enhances negative mood in healthy women. J Psychosom Obstet Gynaecol 2010; 31 (2): 83–9.
26. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78 (1): 16–25.
27. Korfias S, Stranjalis G, Papadimitriou A. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 2006; 13 (30): 3719–31.
28. Korzekwa MI, Lamont JA, Steiner M. Late luteal phase dysphoric disorder and the thyroid axis revisited. J Clin Endocrinol Metab 1996; 81 (6): 2280–4.
29. Kuzelova H, Ptacek R, Macek M. The serotonin transporter gene (5-HTT) variant and psychiatric disorders: review of current literature. Neuro Endocrinol Lett 2010; 31 (1): 4–10.
30. Lonsdorf TB, Rück C, Bergström J. The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (8): 1479–83.
31. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD006586.
32. Magnay JL, El-Shourbagy M, Fryer A.A. Analysis of the serotonin transporter promoter rs25531 polymorphism in premenstrual dysphoric disorder. Am J Obstet Gynecol 2010.
33. Magnay JL, Ismail KM, Chapman G. Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder. Am J Obstet Gynecol 2006; 195 (5): 1254–9.
34. Pearlstein T, Steiner M., Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 2008; 33 (4): 291–301.
35. Pedersen A, Diedrich M, Kaestner F. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (8): 1789–92.
36. Poiană C, Muşat M, Carsote M, Chiriţă C. Premenstrual dysphoric disorder: neuroendocrine interferences. Rev Med Chir Soc Med Nat Iasi 2009; 113 (4): 996–1000.
37. Radhika D. Rible, Daniel R. Mishell Jr, Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. Contraception 2009; 79 (3): 182–8.
38. Rao H, Gillihan SJ, Wang J. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry 2007; 62 (6): 600–6.
39. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003; 28 (Suppl. 3): 39–53.
40. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl. 9): 729–41.
41. Rendas-Baum R, Yang M, Gricar J, Wallenstein GV. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder. Appl Health Econ Health Policy 2010; 8 (2): 129–40.
42. Rosenfeld R, Livne D, Nevo O. Hormonal and volume dysregulation in women with premenstrual syndrome. Hypertension 2008; 51 (4): 1225–30.
43. Schmidt PJ, Grover GN, Roy-Byrne PP. Thyroid function in women with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76 (3): 671–4.
44. Silva CM, Gigante DP, Carret ML, Fassa AG. Population study of premenstrual syndrome. Rev Saude Publica 2006; 40 (1): 47–56.
45. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health 2003; 6: 203–9.
46. Steiner M, Streiner DL, Steinberg S et al. The measurement of premenstrual mood symptoms. J Affect Disord 1999; 53: 269–73.
47. Taneepanichskul S, Jaisamrarn U, Phupong V. Efficacy of Yasmin in premenstrual symptoms. Arch Gynecol Obstet 2007; 275 (6): 433–8.
48. Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health, 2010.
49. Halbreich U, Backstrom T, Eriksson E. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
50. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16 (3): e407–29.
51. Zhang Y, Rothermundt M, Peters M. S100B serum levels and word memory processing in remitted major depression as reflected by brain potentials. Neuropsychobiology 2009; 59 (3): 172–7.
________________________________________________
2. Прилепская В.Н., Межевитинова Е.А. Предменструальный синдром. Гинекол. эндокринол. 2007; 7 (4): 210–4.
3. Татарчук Т.Ф., Венцковская И.Б., Шевчук Т.В. Предменструальный синдром. Эндокринная гинекология. Киев: Заповит, 2003.
4. Эндокринная гинекология. Под ред. Т.Ф.Татарчук, Я.П.Сольский. Киев: Заповит, 2003.
5. Accortt EE, Allen JJ. Frontal EEG asymmetry and premenstrual dysphoric symptomatology. J Abnorm Psychol 2006; 115 (1): 179–84.
6. Baehr E, Rosenfeld P, Miller L, Baehr R. Premenstrual dysphoric disorder and changes in frontal alpha asymmetry. Int J Psychophysiol 2004; 52 (2): 159–67.
7. Benitez A, Gunstad J, Hughes J. Troponin and S100 beta are associated with depression in healthy older adults. Aging Ment Health 2009; 13 (6): 894–8.
8. Bertone-Johnson ER, Chocano-Bedoya PO. Dietary vitamin D intake, 25-hydroxyvitamin D(3) levels and premenstrual syndrome in a college-aged population. J Steroid Biochem Mol Biol 2010.
9. Böttiger BW, Möbes S, Glätzer R. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 2001; 103 (22): 2694–8.
10. Brown J, O’Brien PM, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD001396.
11. Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol 1994; 101: 689–95.
12. Cho SH, Kim J. Efficacy of acupuncture in management of premenstrual syndrome: a systematic review. Complement Ther Med 2010; 18 (2): 104–11.
13. Coffee AL, Kuehl TJ, Sulak PJ. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives. Pharmacotherapy 2008; 28 (5): 576–83.
14. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8 (2): 122–8.
15. Diagnostic and Statistical Manual of mental disorders, DSM-IV) для оценки состояния пациенток (Moira Connolly, Advances in Psychiatric Treatment 2001; 7: 469–77.
16. Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health 2006; 9: 41–9.
17. Eriksson O, Wall A, Marteinsdottir I. Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry Res 2006; 146 (2): 107–16.
18. Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD003415.
19. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996; 65: 97–106.
20. Gonda X, Telek T, Juhász G et al. Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (8): 1782–8.
21. Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr 2008; 13 (7): 566–72.
22. Huo L, Straub RE, Roca C. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007; 62 (8): 925–33.
23. Inoue Y, Terao T, Iwata N. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology (Berl) 2007; 190 (2): 213–9.
24. Jovanovic H, Cerin A, Karlsson P. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006; 148 (2–3): 185–93.
25. Kikuchi H, Nakatani Y, Seki Y. Decreased blood serotonin in the premenstrual phase enhances negative mood in healthy women. J Psychosom Obstet Gynaecol 2010; 31 (2): 83–9.
26. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78 (1): 16–25.
27. Korfias S, Stranjalis G, Papadimitriou A. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 2006; 13 (30): 3719–31.
28. Korzekwa MI, Lamont JA, Steiner M. Late luteal phase dysphoric disorder and the thyroid axis revisited. J Clin Endocrinol Metab 1996; 81 (6): 2280–4.
29. Kuzelova H, Ptacek R, Macek M. The serotonin transporter gene (5-HTT) variant and psychiatric disorders: review of current literature. Neuro Endocrinol Lett 2010; 31 (1): 4–10.
30. Lonsdorf TB, Rück C, Bergström J. The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33 (8): 1479–83.
31. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009; 2: CD006586.
32. Magnay JL, El-Shourbagy M, Fryer A.A. Analysis of the serotonin transporter promoter rs25531 polymorphism in premenstrual dysphoric disorder. Am J Obstet Gynecol 2010.
33. Magnay JL, Ismail KM, Chapman G. Serotonin transporter, tryptophan hydroxylase, and monoamine oxidase A gene polymorphisms in premenstrual dysphoric disorder. Am J Obstet Gynecol 2006; 195 (5): 1254–9.
34. Pearlstein T, Steiner M., Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 2008; 33 (4): 291–301.
35. Pedersen A, Diedrich M, Kaestner F. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (8): 1789–92.
36. Poiană C, Muşat M, Carsote M, Chiriţă C. Premenstrual dysphoric disorder: neuroendocrine interferences. Rev Med Chir Soc Med Nat Iasi 2009; 113 (4): 996–1000.
37. Radhika D. Rible, Daniel R. Mishell Jr, Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. Contraception 2009; 79 (3): 182–8.
38. Rao H, Gillihan SJ, Wang J. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry 2007; 62 (6): 600–6.
39. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003; 28 (Suppl. 3): 39–53.
40. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (Suppl. 9): 729–41.
41. Rendas-Baum R, Yang M, Gricar J, Wallenstein GV. Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder. Appl Health Econ Health Policy 2010; 8 (2): 129–40.
42. Rosenfeld R, Livne D, Nevo O. Hormonal and volume dysregulation in women with premenstrual syndrome. Hypertension 2008; 51 (4): 1225–30.
43. Schmidt PJ, Grover GN, Roy-Byrne PP. Thyroid function in women with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76 (3): 671–4.
44. Silva CM, Gigante DP, Carret ML, Fassa AG. Population study of premenstrual syndrome. Rev Saude Publica 2006; 40 (1): 47–56.
45. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health 2003; 6: 203–9.
46. Steiner M, Streiner DL, Steinberg S et al. The measurement of premenstrual mood symptoms. J Affect Disord 1999; 53: 269–73.
47. Taneepanichskul S, Jaisamrarn U, Phupong V. Efficacy of Yasmin in premenstrual symptoms. Arch Gynecol Obstet 2007; 275 (6): 433–8.
48. Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health, 2010.
49. Halbreich U, Backstrom T, Eriksson E. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
50. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol 2009; 16 (3): e407–29.
51. Zhang Y, Rothermundt M, Peters M. S100B serum levels and word memory processing in remitted major depression as reflected by brain potentials. Neuropsychobiology 2009; 59 (3): 172–7.
Авторы
Р.А.Сасунова, Е.А.Межевитинова
ФГУ Научный центр акушерства, гинекологии и перинатологии им. В.И.Кулакова Минздравсоцразвития РФ, Москва
Federal State Enterprise Research Centre for Obstetrics, Gynaecology and Perinatology named after V.I.Kulakov, Ministry of Public Health and Social Development of the Russian Federation
ФГУ Научный центр акушерства, гинекологии и перинатологии им. В.И.Кулакова Минздравсоцразвития РФ, Москва
________________________________________________
Federal State Enterprise Research Centre for Obstetrics, Gynaecology and Perinatology named after V.I.Kulakov, Ministry of Public Health and Social Development of the Russian Federation
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.